PFE PFIZER INC

NYSE pfizer.com


$ 24.62 $ 0.09 (0.37 %)    

Monday, 03-Nov-2025 12:25:36 EST
QQQ $ 632.11 $ -3.11 (-0.49 %)
DIA $ 473.57 $ -2.57 (-0.54 %)
SPY $ 682.96 $ -2.68 (-0.39 %)
TLT $ 89.53 $ -0.12 (-0.13 %)
GLD $ 368.83 $ 0.02 (0.01 %)
$ 24.65
$ 24.59
$ 24.61 x 3,700
$ 24.62 x 1,815
$ 24.41 - $ 24.69
$ 20.18 - $ 27.69
132,697,441
na
140.15B
$ 0.50
$ 13.03
TBD
na
na ($ 0.07)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-05-2025 06-29-2025 10-Q
2 05-05-2025 03-30-2025 10-Q
3 02-27-2025 12-31-2024 10-K
4 11-04-2024 09-29-2024 10-Q
5 08-05-2024 06-30-2024 10-Q
6 05-08-2024 03-31-2024 10-Q
7 02-22-2024 12-31-2023 10-K
8 11-08-2023 10-01-2023 10-Q
9 08-09-2023 07-02-2023 10-Q
10 05-10-2023 04-02-2023 10-Q
11 02-23-2023 12-31-2022 10-K
12 11-09-2022 10-02-2022 10-Q
13 08-10-2022 07-03-2022 10-Q
14 05-11-2022 04-03-2022 10-Q
15 02-24-2022 12-31-2021 10-K
16 11-12-2021 10-03-2021 10-Q
17 08-12-2021 07-04-2021 10-Q
18 05-13-2021 04-04-2021 10-Q
19 02-25-2021 12-31-2020 10-K
20 11-05-2020 09-27-2020 10-Q
21 08-06-2020 06-28-2020 10-Q
22 05-07-2020 03-29-2020 10-Q
23 02-27-2020 12-31-2019 10-K
24 11-07-2019 09-29-2019 10-Q
25 08-08-2019 06-30-2019 10-Q
26 05-09-2019 03-31-2019 10-Q
27 02-28-2019 12-31-2018 10-K
28 11-08-2018 09-30-2018 10-Q
29 08-09-2018 07-01-2018 10-Q
30 05-10-2018 04-01-2018 10-Q
31 02-22-2018 12-31-2017 10-K
32 11-09-2017 10-01-2017 10-Q
33 08-10-2017 07-02-2017 10-Q
34 05-11-2017 04-02-2017 10-Q
35 02-23-2017 12-31-2016 10-K
36 11-10-2016 10-02-2016 10-Q
37 08-11-2016 07-03-2016 10-Q
38 05-12-2016 04-03-2016 10-Q
39 02-29-2016 12-31-2015 10-K
40 11-05-2015 09-27-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

- Reuters

Core News & Articles

- Reuters

 biontech-sees-higher-2025-sales-driven-by-bristol-myers-partnership

BioNTech reports a Q3 loss but boosts 2025 revenue forecast to €2.6–2.8 billion, driven by Bristol Myers collaboration and cost...

 pfizer-accuses-novo-nordisk-of-antitrust-violations-in-metsera-takeover-battle

Pfizer sues Metsera and Novo Nordisk, alleging breach of contract and antitrust violations over a rival $9 billion bid challeng...

 top-stocks-with-earnings-this-week-joby-ionq-amd-and-more

Retail investors are preparing for another busy week of earnings season with more than 1,600 companies set to report through Fr...

 how-to-earn-500-a-month-from-pfizer-stock-ahead-of-q3-earnings

Pfizer offers an annual dividend yield of 6.98%, or $1.72 a year. Here's how investors can pocket a regular $500 monthly.

Core News & Articles

Pfizer Inc. today announced that it has filed a second lawsuit against Metsera, Inc., its controlling stockholders, and Novo No...

Core News & Articles

-Reuters

Core News & Articles

Pfizer Inc. today announced that it has filed a lawsuit against Metsera, Inc., its Board of Directors, and Novo Nordisk, S.A. i...

Core News & Articles

Pfizer Inc. (NYSE:PFE) today announced the U.S. Federal Trade Commission has granted early termination of the waiting period un...

 eli-lilly-extends-lead-in-150b-obesity-drug-race-as-novo-pfizer-clash--heres-how-etfs-stand-to-gain

As Eli Lilly, Novo Nordisk, and Pfizer battle for dominance in the obesity-drug market, these ETFs are offering exposure to the...

Core News & Articles

https://www.semafor.com/article/10/30/2025/pfizer-mulls-suing-metsera-novo-over-topping-bid

 pfizer-blasts-novo-nordisks-9-billion-counteroffer-for-metsera-as-reckless

Novo Nordisk's $9 billion offer for Metsera challenges Pfizer's existing merger deal, prompting sharp criticism and pot...

Core News & Articles

- Reuters 

Core News & Articles

Pfizer Inc. (NYSE:PFE) is aware of the reckless and unprecedented proposal by Novo Nordisk A/S (NYSE:NVO) to acquire Metsera, I...

 i-still-cant-believe-its-around-cramer-rips-plug-power

Mad Money Lightning Round: Jim Cramer says Sempra (SRE) is a buy, supported by Wells Fargo's Overweight rating. Pfizer (PFE...

 ken-paxton-alleges-johnson--johnson-misled-mothers-on-tylenol-safety

Texas Attorney General Ken Paxton sued Johnson & Johnson and Kenvue, alleging Tylenol was deceptively marketed as safe for ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION